Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT

Hicham Skali, Edward M. Dwyer, Robert Goldstein, Mark Haigney, Ronald Krone, Marrick Kukin, Edgar Lichstein, Scott McNitt, Arthur J. Moss, Marc A. Pfeffer, Scott D. Solomon

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Aims Hospitalization for worsening heart failure (HF) is known to increase mortality and morbidity risk and has been frequently used as an endpoint in randomized clinical trials. Whether outpatient management of HF exacerbation carries similar prognostic and therapeutic information is less well known, but could be important for the design of trials that use HF hospitalization as an endpoint. Methods and results MADIT-CRT randomized patients with mild HF symptoms to resynchronization therapy vs. control with an average follow-up of 3.3 years and a total of 191 deaths. HF events were centrally adjudicated for receiving i.v. decongestive therapy in an outpatient setting, or an augmented HF regimen during a hospital stay. Patients were compared according to whether their first HF was an out- or inpatient event. The first primary event was non-fatal outpatient HF, non-fatal inpatient HF, and death in 52, 331, and 78 patients, respectively. Patients with inpatient HF tended to be older and more likely to have HF of ischaemic aetiology than subjects who developed outpatient HF events. The risk of death following either type of non-fatal HF events was extremely high [hazard ratio (HR) 12.4, 95% confidence interval (CI) 9.1-16.9 for inpatient HF; HR 10.7, 95% CI 6.1-18.7 for outpatient HF] compared with subjects without non-fatal HF events. Allocation to CRT-D was associated with significant reduction in both types of HF. Conclusion Outpatient management of worsening HF portends a high risk of death, similar to inpatient HF events, and may be equally sensitive to the effects of therapy. These findings suggest that outpatient HF events should be considered in publicly reported outcomes measures and future HF clinical trials. Trial Registration NCT01294449.

Original languageEnglish
Pages (from-to)560-565
Number of pages6
JournalEuropean Journal of Heart Failure
Volume16
Issue number5
DOIs
StatePublished - May 2014

Keywords

  • Clinical trials
  • Endpoint
  • Heart failure
  • Outpatient

Fingerprint Dive into the research topics of 'Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT'. Together they form a unique fingerprint.

Cite this